Contributor Page
Ropes & Gray LLP
 
Email  |  Website  |  Articles
Contact Details
Tel: +1 212 5969000
Fax: +1 212 5969090
1211 Avenue of the Americas
New York
New York
NY 10036-8704
United States
By Ropes & Gray LLP's Health Care Practice, Ropes & Gray LLP's Life Sciences Practice Group
On January 19, 2017, the U.S. Department of Health and Human Services (HHS), together with 15 other federal Departments and Agencies, issued a final rule to revise and modernize the federal Policy for the Protection of Human Subjects (the Common Rule), the set of federal regulations governing the conduct of clinical research involving human subjects.
By Alexandre Rene
Alex Rene, co-chair of Ropes & Gray's anti-corruption and international risk practice, discusses likely FCPA enforcement activity under the Trump administration.
By Katherine Wang
China will launch further reforms in the pharmaceutical sector as part of the healthcare reform initiatives announced by the State Council in its February 9, 2017 Circular on Several Opinions Concerning Further Reforms of the Policies Governing Drug Production, Circulation and Usage (the "Circular No.13").
By Deborah Monson, Jeremy A. Liabo
On February 6, 2017, the Division of Market Oversight of the U.S. Commodity Futures Trading Commission (the "CFTC") issued temporary no-action relief from the notice filing requirements...
By Colleen Conry
Colleen Conry, Ropes & Gray government enforcement partner, provides insights on what to expect with enforcement activity under the Trump administration and a Jeff Sessions led Department of Justice.
By John Bueker, Kirsten Mayer, Cassandra LaRussa
On December 13, 2016, in United States ex rel Simoneaux v. E.I. DuPont de Nemours & Co., the Fifth Circuit rejected an expansive construction of "reverse" false claims and . . .
By Patrick Sinclair, Geoffrey M. Atkins, Nathaniel Lai
The Hong Kong Government has recently proposed to expand its AML laws. This is expected to assist Hong Kong in keeping pace with AML developments in other financial centers...
By Kirsten Mayer, John Bueker, Michael B. Homer
In August 2009, Pfizer settled a number of cases alleging FCA violations concerning several drugs, including an antipsychotic drug called Geodon.
By Ropes & Gray LLP's ERISA Practice
On February 3, 2017, President Trump signed a presidential memorandum directing the U.S. Department of Labor (the "DOL") to examine its new fiduciary rule.
By Matthew Rizzolo
Over the past decade, intellectual property issues have often taken center stage in Congress.
By Michael Littenberg, Isabel K.R. Dische, Amanda Raad, Marcus Thompson
Starting this year, a significant number of fund managers based all over the world will be among the approximately 12,000 companies that will be required to publish an annual statement...
By Ropes & Gray LLP's Tax Controversy Practice Group, Ropes & Gray LLP's Tax Practice Group
On Tuesday, January 31, the IRS announced the rollout of thirteen initial compliance campaigns that will be undertaken by its Large Business and International Division.
By Katherine Wang
Recently China's Food and Drug Administration ("CFDA") released the Provisions for Medical Device Recall ("New Recall Rules").
By Ropes & Gray LLP's Government Enforcement, Health Care & Appellate & Supreme Court Practice Group
Earlier today, the UK government published an official policy paper (the White Paper) setting out the government's approach to leaving the European Union (EU).
By Ropes & Gray LLP's Investment Management Practice Group
On January 25, 2017, the SEC staff issued a letter confirming that, for the purposes of Rule 12d1-2, the term "group of investment companies" does not include closed-end funds and, therefore, . . .
Contributor's Topics
More...